Published in Naunyn Schmiedebergs Arch Pharmacol on February 04, 2003
Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front Psychol (2012) 1.20
Panic disorder: is the PAG involved? Neural Plast (2009) 0.95
Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. PLoS One (2009) 0.88
Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats. Psychopharmacology (Berl) (2004) 0.87
Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine. Psychopharmacology (Berl) (2007) 0.84
Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl) (2006) 0.84
Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol (2004) 0.84
Duloxetine: a new pharmacologic therapy for stress urinary incontinence. Rev Urol (2004) 0.79
Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment. J Neural Transm (Vienna) (2012) 0.78
Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology (Berl) (2004) 0.77
Neonatal administration of buspiron causes changes in intermale aggression of adult mice. Dokl Biol Sci (2004) 0.75
Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord (2000) 2.26
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol (1999) 1.56
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) (2002) 1.46
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol (1994) 1.34
Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology (1980) 1.27
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry (1999) 1.20
LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology (1993) 1.19
Pharmacology of antidepressants. J Clin Psychopharmacol (1997) 1.18
Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci (1994) 1.16
Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) (1997) 1.14
Activity of brain serotonergic neurons in the behaving animal. Pharmacol Rev (1991) 1.12
Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord (1996) 1.11
Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol (1996) 1.11
Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther (1993) 1.11
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther (2001) 1.05
Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther (1995) 1.01
Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.98
In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther (1997) 0.97
Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett (1994) 0.95
Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther (1995) 0.95
Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J Neurochem (1997) 0.94
Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol (1998) 0.93
Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse (1993) 0.92
Serotonergic dorsal raphe neurons cease firing by disfacilitation during paradoxical sleep. Neuroreport (2000) 0.89
Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem (1997) 0.89
In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse (1994) 0.88
Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol (2000) 0.86
Behavioral state-related changes of extracellular serotonin concentration in the dorsal raphe nucleus: a microdialysis study in the freely moving cat. Brain Res (1994) 0.84
Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology (1999) 0.84
Extracellular serotonin levels change with behavioral state but not with pyrogen-induced hyperthermia. J Neurosci (1991) 0.83
Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology (1995) 0.83
Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol (1999) 0.81
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline. Eur J Pharmacol (1999) 0.81
Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology (1995) 0.80
Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol (1999) 0.79
The comparison of fluoxetine and nisoxetine with tricyclic antidepressants in blocking the neurotoxicity of p-chloroamphetamine and 6-hydroxydopamine in the rat brain. Res Commun Chem Pathol Pharmacol (1976) 0.79
In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies. J Pharmacol Exp Ther (1996) 0.78
Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.77
Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Br J Pharmacol (1998) 0.76
Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy. Clin Neuropharmacol (1998) 0.76
Effects of adrenergic drugs on raphe unit activity in freely moving cats. Eur J Pharmacol (1981) 0.76
In vivo characterization of the putative 5-HT1A receptor antagonist SDZ 216,525 using two models of somatodendritic 5-HT1A receptor function. Neuropharmacology (1994) 0.75
Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett (2005) 1.08
Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther (2002) 1.05
Influence of inhibitory and excitatory inputs on serotonin efflux differs in the dorsal and median raphe nuclei. Brain Res (2003) 0.97
GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther (2002) 0.95
mu-Opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res (2005) 0.90
Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain. Basic Clin Pharmacol Toxicol (2010) 0.82
Changes in gamma-aminobutyric acid tone and extracellular serotonin in the dorsal raphe nucleus over the rat estrous cycle. Neuroendocrinology (2004) 0.81
Modeling energy intake by adding homeostatic feedback and drug intervention. J Pharmacokinet Pharmacodyn (2014) 0.80
Binding properties of antagonists to cannabinoid receptors in intact cells. Fundam Clin Pharmacol (2011) 0.78
Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese mice. Obesity (Silver Spring) (2014) 0.78
Osteoporosis in MCHR1-deficient mice. Biochem Biophys Res Commun (2004) 0.77
Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors. Br J Pharmacol (2003) 0.77
Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy. Eur Neuropsychopharmacol (2002) 0.75
Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. Endocrinology (2014) 0.75
Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorg Med Chem Lett (2009) 0.75